Cautious on Yahoo! ...
Health Care: Drugs
Telik Inc. (TELK: NASDAQ)
$1.32 0.00 | 0.00%
05/23/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -7.97M | -12.02M | -24.72M | -23.69M |
| Operating Gains/Losses | 0.00 | 0.00 | 31.00K | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 20.00K | 189.00K | 2.00K | -178.00K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 42.00K | -823.00K | 742.00K | -1.39M |
| (Decrease) Increase In Other Current Liabilities | -1.59M | -288.00K | -535.00K | -1.53M |
| (Increase) Decrease In Other Working Capital | 0.00 | -1.44M | -97.00K | 0.00 |
| Other Non-Cash Items | 696.00K | 1.56M | 7.45M | 1.85M |
| Net Cash From Continuing Operations | -8.74M | -12.76M | -16.72M | -24.12M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.74M | -12.76M | -16.72M | -24.12M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 5.00K | 659.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 2.40M | 13.64M | 15.28M | -14.24M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 2.04M | 393.00K | 64.00K | 47.00K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | -3.10M | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 2.04M | 393.00K | -3.04M | 47.00K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -4.30M | 1.28M | -4.48M | -38.31M |
Portfolios with TELK
- Portfolio NameUser Type
- Uservlady 1
- ContributorBarron's Insider Purchases ...
- UserASCO 2010
- UserASCO 2009 Nymph's Watch List.
- UserPeter J. Lotti Portfolio 1
- UserPete'spicks
- ContributorBarron's Activist Stocks 11...
- ContributorBarron's Activist Stocks 11...
- UserC070707
- Usergonzomoney
Latest TELK Headlines from TheStreet
- Icahn Should Hang It Up: Activist 10.28.09 | 06:10 am
- Insider Sells $20.2 Million of National Semi 01.16.09 | 09:01 am
- Insider Sells $1.2M of Noven Pharmaceuticals 01.06.09 | 09:01 am
- Feuerstein's Biotech-Stock Mailbag 04.05.08 | 11:04 am
- Feuerstein's Biotech-Stock Mailbag 11.03.07 | 11:11 am
- Monday's Health Winners & Losers 10.15.07 | 04:10 pm
- Feuerstein's Biotech-Stock Mailbag 09.29.07 | 11:09 am
- Telik Fails Ethics Test 08.09.07 | 08:08 am
- These Homebuilder Stocks Could Soar 07.13.07 | 08:07 am
- Stockpickr: How to Trade Like Carl Icahn 06.20.07 | 12:06 am
Press Releases for TELK
- Telik Announces Preliminary Agreement On Design Of Phase 3 Registration Trial Of Telintra® In Low To Intermediate-1 Risk Myelodysplastic Syndrome - PR Newswire 01.22.13 | 05:01 pm
- Telik Announces Orphan Designation Of Telintra® For Treatment Of Myelodysplastic Syndrome - PR Newswire 01.11.13 | 07:01 pm
- Telik Announces Telintra® Clinical Publication At The 54th Annual Meeting Of The American Society Of Hematology - PR Newswire 12.12.12 | 04:12 pm
- Telik Announces The Publication Of Two Reports In The Journal Of Hematology & Oncology Describing The Results Of A Clinical Study Of Telintra® In Combination With Revlimid® And A Genomic Study Designed To Identify Genes That Predict Response To Telintra In Patients With Myelodysplastic Syndrome - PR Newswire 05.15.12 | 06:05 am
- Telik Regains Compliance With Minimum Bid Price Requirement - PR Newswire 04.17.12 | 04:04 pm
- Telik Announces Reverse Split Of Common Stock - PR Newswire 03.30.12 | 01:03 pm
- Telik Announces Expansion Of Phase 2 Trial Of Telcyta In Hematologic Malignancies - PR Newswire 02.21.12 | 09:02 am
- Telik Announces Presentation And Webcast At 14th Annual BIO CEO & Investor Conference - PR Newswire 02.08.12 | 09:02 am
- Telik Announces Presentation And Webcast At 5th Annual OneMedForum Conference - PR Newswire 01.04.12 | 09:01 am
- Telik Announces The Results Of Genetic Signature Studies Of Myelodysplastic Syndrome Patients Likely To Respond To Telintra® (Ezatiostat Hydrochloride, TLK199) At The Annual Meeting Of The American Society Of Hematology - PR Newswire 12.13.11 | 09:12 am
Partner Headlines for TELK
- 5 Stocks Trading Below Net Cash - Part VI - Seeking Alpha 08.28.12 | 09:08 am
- 19 High Growth Micro Cap Stocks Under $10 - Seeking Alpha 01.23.11 | 07:01 am
